Synaptogenix announced that it received notice from The Nasdaq Stock Market on April 22, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market. On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNPX:
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
- Synaptogenix increases stake in psilocybin drug discovery company
- Synaptogenix Inc trading halted, news pending
- Synaptogenix implementing reverse stock split to maintain Nasdaq listing